Relative risk

How much more (or less) likely something is in one group compared with another. A relative risk of 2 means twice as likely; 0.5 means half as likely.

Also called: rr, risk ratio, relative risk ratio

Related words confidence interval hazard ratio odds ratio absolute risk

Topics Research

Questions people ask

Does Crohn's run in families?

It can. The NHS says you may be more likely to get Crohn's if other people in your family have it. Crohn's & Colitis UK says researchers have found more than 200 gene variations that affect the risk, many involved in the immune system. Guts UK says about one in five people with Crohn's has a relative with it, but that genes alone do not decide who gets it.

Sources

Where to read more

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis

Cochrane Systematic review Jun 2026 Patients and professionals

An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.

Topics Biologics and newer medicines Research

Jargon explained network meta-analysis relative risk number needed to treat biosimilar

Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018

Alimentary Pharmacology & Therapeutics Data May 2020 Patients and professionals

Using UK GP records from 2000 to 2017, this study found Crohn's became more common, rising from about 220 to 400 per 100,000 people. It predicted about 1 in 90 people in the UK would have IBD by 2025. Colitis was linked to a higher risk of bowel cancer, and both conditions to a somewhat higher risk of death than people without IBD.

Topics About Crohn's disease Cancer risk and screening Research

Jargon explained epidemiology prevalence hazard ratio all-cause mortality

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial

The Lancet Gastroenterology & Hepatology Study Oct 2020 Patients and professionals

A longer look back at the people in the LIR!C trial. It supported keyhole removal of the end of the small bowel as a real option for people with short, mainly inflamed (not narrowed) disease when standard medicines have not worked. In both groups, adding an immunosuppressant was linked to the benefit lasting longer.

Topics Surgery Biologics and newer medicines

Jargon explained retrospective hazard ratio immunomodulator

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE)

The Lancet Study Jun 2022 Patients and professionals

One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.

Topics Biologics and newer medicines Research

Jargon explained head-to-head trial biologic-naive confidence interval

Search everything for "relative risk"